Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Sabarinath Venniyil Radhakrishnan MD

Sabarinath Venniyil Radhakrishnan MD profile photo picture

Assistant Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center
Member of the Center for Immunology

View Curriculum Vitae

Publications (16)

  • Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. (Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D'Souza A, Hari P) Blood Adv 2022 Apr 26;6(8):2466-2470 PMID: 34933344 PMCID: PMC9043928 SCOPUS ID: 2-s2.0-85129331026 12/22/2021       25 Citations
  • The Prolyl Hydroxylase Inhibitor Dimethyl Oxalyl Glycine Decreases Early Gastrointestinal GVHD in Experimental Allogeneic Hematopoietic Cell Transplantation. (Palaniyandi S, Kumari R, Venniyil Radhakrishnan S, Strattan E, Hakim N, Munker R, Kesler MV, Hildebrandt GC) Transplantation 2020 Dec;104(12):2507-2515 PMID: 32639407 PMCID: PMC8139022 SCOPUS ID: 2-s2.0-85096509107 07/09/2020       5 Citations
  • CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. (Radhakrishnan SV, Luetkens T, Scherer SD, Davis P, Vander Mause ER, Olson ML, Yousef S, Panse J, Abdiche Y, Li KD, Miles RR, Matsui W, Welm AL, Atanackovic D) Nat Commun 2020 Feb 07;11(1):798 PMID: 32034142 PMCID: PMC7005855 SCOPUS ID: 2-s2.0-85079080842 02/09/2020       41 Citations
  • A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. (Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G) Cell Transplant 2019 Dec;28(12):1624-1631 PMID: 31619057 PMCID: PMC6923548 SCOPUS ID: 2-s2.0-85076876281 10/18/2019    
  • In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. (Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Kröger N, Luetkens T) Leukemia 2020 Jan;34(1):317-321 PMID: 31409922 SCOPUS ID: 2-s2.0-85070798814 08/15/2019       30 Citations
  • The role of surface molecule CD229 in Multiple Myeloma. (Olson M, Radhakrishnan SV, Luetkens T, Atanackovic D) Clin Immunol 2019 Jul;204:69-73 PMID: 30326256 SCOPUS ID: 2-s2.0-85055712528 10/17/2018       9 Citations
  • Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. (Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D) Oncoimmunology 2017;6(5):e1308618 PMID: 28638731 PMCID: PMC5468000 SCOPUS ID: 2-s2.0-85019019970 06/24/2017       16 Citations
  • Elotuzumab as a novel anti-myeloma immunotherapy. (Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D) Hum Vaccin Immunother 2017 Aug 03;13(8):1751-1757 PMID: 28604269 PMCID: PMC5557243 SCOPUS ID: 2-s2.0-85020548304 06/13/2017       4 Citations
  • Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. (Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T) Oncotarget 2017 Jul 25;8(30):49253-49263 PMID: 28512269 PMCID: PMC5564765 SCOPUS ID: 2-s2.0-85025814243 05/18/2017       9 Citations
  • Current Strategies for the Immunotherapy of Multiple Myeloma. (Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D) Oncology (Williston Park) 2017 Jan 15;31(1):55-63 PMID: 28090624 SCOPUS ID: 2-s2.0-85050440905 01/17/2017    
  • Immunotherapies targeting CD38 in Multiple Myeloma. (Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T) Oncoimmunology 2016;5(11):e1217374 PMID: 27999737 PMCID: PMC5139636 SCOPUS ID: 2-s2.0-84992493220 12/22/2016       31 Citations
  • Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. (Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T) Br J Haematol 2016 Mar;172(5):685-98 PMID: 26791002 SCOPUS ID: 2-s2.0-84958899793 01/23/2016       55 Citations
  • A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population. (Radhakrishnan SV, Hildebrandt GC) Curr Hematol Malig Rep 2015 Mar;10(1):8-17 PMID: 25662904 SCOPUS ID: 2-s2.0-84925502984 02/11/2015       3 Citations
  • Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation. (Radhakrishnan SV, Palaniyandi S, Mueller G, Miklos S, Hager M, Spacenko E, Karlsson FJ, Huber E, Kittan NA, Hildebrandt GC) Biol Blood Marrow Transplant 2015 Jan;21(1):30-8 PMID: 25445642 SCOPUS ID: 2-s2.0-84927125235 12/03/2014       16 Citations
  • Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. (Schwab L, Goroncy L, Palaniyandi S, Gautam S, Triantafyllopoulou A, Mocsai A, Reichardt W, Karlsson FJ, Radhakrishnan SV, Hanke K, Schmitt-Graeff A, Freudenberg M, von Loewenich FD, Wolf P, Leonhardt F, Baxan N, Pfeifer D, Schmah O, Schönle A, Martin SF, Mertelsmann R, Duyster J, Finke J, Prinz M, Henneke P, Häcker H, Hildebrandt GC, Häcker G, Zeiser R) Nat Med 2014 Jun;20(6):648-54 PMID: 24836575 SCOPUS ID: 2-s2.0-84902203966 05/20/2014       209 Citations
  • Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from latent infection. (Palaniyandi S, Radhakrishnan SV, Karlsson FJ, Stokes KY, Kittan N, Huber E, Hildebrandt GC) PLoS One 2013;8(4):e61841 PMID: 23596528 PMCID: PMC3626592 SCOPUS ID: 2-s2.0-84876195809 04/19/2013       11 Citations
    • Last update: 04/03/2024